New data from Guidepoint Qsight has revealed that non-surgical aesthetic spending reached $17.5 billion in 2024, up from $17.2 billion in 2023. Driven by strong patient demand, rising per-visit costs, and a shift toward minimally invasive treatments, the increase signals a broader trend toward treatments that offer minimal downtime and high value.
The top procedure is neurotoxins, accounting for 32 percent of total patient spending and generating $5.6 billion. In addition, regenerative procedures are gaining ground, with biostimulatory injectables reaching $720 million and exosomal therapies at medical spas rising 6 percent this year. GLP-1 weight loss treatments have seen major growth, with monthly spending surging tenfold since 2021 to reach $160 million.